Cholecystokinin-induced pancreatic growth involves the high-affinity CCK receptor and concomitant activation of tyrosine kinase and phospholipase D.
Rivard
N
N
Département de biologie, Université de Sherbrooke, Québec, Canada.
Rydzewska
G
G
Morisset
J
J
D000818:Animals; D002108:Ceruletide / Q000008:administration & dosage / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism; D004789:Enzyme Activation; D007262:Infusions, Intravenous; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology / Q000502:physiology*; D010739:Phospholipase D / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D011506:Proteins / Q000378:metabolism; D012313:RNA / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D012844:Sincalide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D011506:Proteins; D011949:Receptors, Cholecystokinin; C058451:JMV 180; D012313:RNA; D002108:Ceruletide; D004247:DNA; D011505:Protein-Tyrosine Kinases; D010739:Phospholipase D; D012844:Sincalide